FSD Pharma Provides Update on Operations, Strategy and Leadership

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD”), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes. read more

FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal

– FSD enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop –
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD”), a licensed producer under the Cannabis Act, announced today that it has entered into a supply agreement (the “Agreement”) with Canntab Therapeutics Ltd. (“Canntab”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower. read more

FSD Pharma Signs Collaboration and Profit-Sharing Agreement with Pharmastrip for Production and Delivery of Organic Medical Cannabis Infused in Oral Thin Film Strips

– FSD receives exclusive, perpetual license to manufacture and sell oral film strips in Canada
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company), a licensed producer under the Cannabis Act, announced today that it has completed a strategic investment of $1.5 million in Pharmastrip Corp. and signed a definitive collaboration and profit sharing agreement with the company, effective January 23, 2019. Under the terms of the agreement, FSD will install Pharmastrip proprietary equipment at its facility in Cobourg, Ontario. FSD will use the equipment to manufacture organic medical cannabis infused in oral thin film strips. Pharmastrip will grant FSD an exclusive, perpetual license to manufacture and sell the oral thin film strips in Canada. read more

FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae

PHARMA GRADE PROCESS COULD REDUCE THE PRODUCTION TIME FOR TARGETED CANNABINOID MOLECULE(S
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTC:  FSDDF) (“FSD Pharma“) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest“) (collectively, the “Parties“), a technology company which has developed an algal-based flexible production platform capable of producing health products, are pleased to announce that they have signed a non-binding letter of intent (“LOI“). The parties intend to enter into a definitive agreement (the “Collaborative Research Agreement“), under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids (the “Project Cannabinoids“), the Parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids. read more

FSD Pharma Congratulates High Tide Inc. for Signing LOI with Winner of Ontario Retail License Lottery to Operate Cannabis Retail Store

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: OK9) (“FSD Pharma” or the “Company”) would like to congratulate High Tide Inc. (“High Tide”) for entering into a letter of intent with a winner of one of the 25 opportunities to apply for a license to operate a cannabis retail store (the “Winner”) as a result of the Alcohol and Gaming Commission of Ontario’s Expression of Interest Application Lottery conducted on January 11, 2019. Under the terms of the LOI, High Tide will acquire a minority interest in the Winner and will assist the Winner with establishing and operating a cannabis retail store in Ontario. read more

FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange (“CSE”) today under the stock symbol “LOVE”. FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares”) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. read more

FSD Pharma Announces Holdings in Cannara Biotech Inc.

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma (“FSD“) announced today that, in connection with the business combination (the “Business Combination“) completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the “Issuer“), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares“) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. read more

FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

Company in position for pre-sales license inspection, last step to issuance
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations. read more

FSD Pharma Responds to Therapix Termination of Binding LOI

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) in response to Therapix Biosciences’ termination of the company’s binding letter of intent (LOI) to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement: read more